Used in pharmaceutical research as a potent and selective inhibitor of dipeptidyl peptidase-4 (DPP-4), this compound plays a key role in the development of treatments for type 2 diabetes. By inhibiting DPP-4, it enhances the activity of incretin hormones such as GLP-1, leading to improved glucose control, increased insulin secretion, and reduced glucagon levels in a glucose-dependent manner. Its structure supports high oral bioavailability and prolonged duration of action, making it a valuable candidate for once-daily dosing in antidiabetic therapies. It is also studied for potential anti-inflammatory and cardioprotective effects associated with DPP-4 inhibition.